# Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).

> **NCT04225325** · PHASE4 · UNKNOWN · sponsor: **ADRIANO LAZZARIN, MD** · enrollment: 112 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **COMBINATION_PRODUCT:** SYMTUZA
- **COMBINATION_PRODUCT:** DESCOVY+DOLUTEGRAVIR
- **COMBINATION_PRODUCT:** SYMTUZA+DOLUTEGRAVIR

## Key facts

- **NCT ID:** NCT04225325
- **Lead sponsor:** ADRIANO LAZZARIN, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-07
- **Primary completion:** 2019-09-30
- **Final completion:** 2021-06-14
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2020-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04225325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04225325, "Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04225325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*